BTIG Maintains Buy on Boston Scientific, Lowers Price Target to $56

Benzinga Newsdesk www.benzinga.com Negative 66.7%

Neg 66.7% Neu 0% Pos 0%

BTIG analyst Marie Thibault maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $60 to $56.